References of "Paulus, Patrick"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailLes neuroblastomes de l'enfant. A propos de 23 cas.
Piette, Catherine ULg; Dresse, Marie-Françoise ULg; Forget, Patricia ULg et al

in Revue Médicale de Liège (2005), 60(3), 173-80

In this retrospective study, we analyse epidemiology, clinical symptoms and therapeutic results in a group of 23 children with neuroblastoma. Half of them were less than 2 years of age; in 19 of 23, the ... [more ▼]

In this retrospective study, we analyse epidemiology, clinical symptoms and therapeutic results in a group of 23 children with neuroblastoma. Half of them were less than 2 years of age; in 19 of 23, the primitive tumour was abdominal; 35% of them were initially metastatic. The overall survival was 83% at 5 years and the event free survival, 75% at 5 years. Pronostic factors are age, extension of the disease at diagnosis, biologic parameters and genetic study of the neuroblast cells (amplification of N-myc oncogen). Our study shows the deleterious effect of bone lesions. [less ▲]

Detailed reference viewed: 158 (4 ULg)
Full Text
See detailRadiothérapie métabolique des douleurs osseuses d'origine métastatique : nouveaux traitements, nouvelles pratiques
Hustinx, Roland ULg; Paulus, Patrick

in Annales de l'Association Belge de Radioprotection = Annalen van de Belgische Vereniging voor Stralingsbescherming (2003), 28

Le traitement palliatif des douleurs osseuses liées à la dissémination métastatique s'est récemment enrichi d'une molécule, le 153Sm-EDTMP (Quadramet). Le traitement classique faisait appel au Strontium ... [more ▼]

Le traitement palliatif des douleurs osseuses liées à la dissémination métastatique s'est récemment enrichi d'une molécule, le 153Sm-EDTMP (Quadramet). Le traitement classique faisait appel au Strontium-89 (Métastron). Alors que ce dernier est un émetteur bêta pur, de longue demi-vie (50,5 jours), le 153Sm émet également un rayonnement gamma de 103 keV, et sa période physique est de 1,95 jours. Dans cet exposé nous envisagerons, du point de vue de la radioprotectio, les propriétés pharmacocinétiques du radiopharmaceutique et les caractéristiques physiques du 153Sm. Nous relaterons également l'expérience acquise dans notre centre avec le 186Re-HEDP. [less ▲]

Detailed reference viewed: 49 (2 ULg)
Full Text
Peer Reviewed
See detailIntérêt de la tomographie a émission de positons dans l'évaluation des tumeurs digestives
Hustinx, Roland ULg; Paulus, Patrick; Daenen, Frédéric ULg et al

in Revue Médicale de Liège (1999), 54(12), 925-30

Imaging and endoscopic techniques have taken an increasing part in the management of gastroenterological disorders. Among these techniques, FDG-PET imaging has emerged as a powerful tool in the management ... [more ▼]

Imaging and endoscopic techniques have taken an increasing part in the management of gastroenterological disorders. Among these techniques, FDG-PET imaging has emerged as a powerful tool in the management of several cancer diseases, including tumors of the digestive tract. In particular, the role of PET for diagnosing and staging recurrent colorectal cancers, and for differentiating mass forming pancreatitis from carcinoma is now well established. In this review, we will briefly discuss the place of PET imaging in the work-up of the tumors of the digestive tract. [less ▲]

Detailed reference viewed: 23 (2 ULg)
Full Text
Peer Reviewed
See detailIntérêt de la tomographie à émission de positons dans l'évaluation des tumeurs gastro-intestinales
Rigo, Pierre ULg; Albérini, Jean-Louis; Hustinx, Roland ULg et al

in Acta Endoscopica (1999), 29(2), 129-138

La TEP au 18FDG présente de nombreuses indications dans l'évaluation des tumeurs digestives. Son rôle principal concerne le bilan d'extension des récidives tumorales démontrées ou suspectées mais des ... [more ▼]

La TEP au 18FDG présente de nombreuses indications dans l'évaluation des tumeurs digestives. Son rôle principal concerne le bilan d'extension des récidives tumorales démontrées ou suspectées mais des indications plus ponctuelles concernent évalement le diagnostic différentiel des masses pancréatiques et le bilan du cancer de l'oesophage. Le principal avantage de la TEP résulte de la nature métabolique du signal indépendant et complémentaire des modifications anatomiques visibles en imagerie classique. Un autre avantage est lié à l'examen du corps entier aujourd'hui pratiqué systématiquement. La TEP trouve dès lors sa place en première ligne dans ses différentes indications. [less ▲]

Detailed reference viewed: 28 (1 ULg)
Full Text
Peer Reviewed
See detailIntérêt clinique de la tomographie à émission de positons dans la détection et le bilan d'extension des lymphomes non Hodgkiniens de malignité intermédiaire ou élevée
Najjar, Fadi; Jerusalem, Guy ULg; Paulus, Patrick et al

in Médecine Nucléaire : Imagerie Fonctionnelle et Métabolique (1999), 23

Accurate staging of non-Hodkin's lymphoma (NHL) is important for treatment management. We studied 53 patients (40 patients at initial diagnosis and 13 patients at disease recurrence) with ... [more ▼]

Accurate staging of non-Hodkin's lymphoma (NHL) is important for treatment management. We studied 53 patients (40 patients at initial diagnosis and 13 patients at disease recurrence) with histopathologically proven aggressive NHL to assess the value of whole-body FDG positron emission tomography (PET) as an imaging modality for staging and restaging NHL. All patients in this comparative analysis were submitted to clinical examination ; computed tomography (CT) and whole-body PET studies before starting the treatment. Results : whole-body FDG-PET seems to be more sensitive than clinical examination and CT imaging for detection of lymph node regions infiltrated by NHL : there were 98 abnormal peripheral lymph node regions senn by FDG-PET : 59 observed by clinical examination and 39 clinically undetected. The clinical examination showed 9 additional nodal lesions not seen by PET. Of 77 thoracic and abdominopelvic trated by CT. The CT studies showed 5 additional nodal lesions. Extranodal lymphomatous localisations in the liver (n=5), spleen (n=14), lungs (n=8), pleura (n=9), digestive tract (n=4), pelvis (n=2) and other sites (n=9) were identified by PET. Bone marrow infiltration demonstrated by PET was confirmed by biopsy in 6/10 patients, however known medullary invasion was not seen by PET imaging in 5 patients. Conclusion : whole-body FDG-PET without attenuation correction is an efficient, non-invasive method for staging and restaging aggressive NHL but marrow biopsy remains to be performed in addition to PET. [less ▲]

Detailed reference viewed: 63 (1 ULg)
Full Text
Peer Reviewed
See detail18fdg-Pet for the Assessment of Primary Head and Neck Tumors: Clinical, Computed Tomography, and Histopathological Correlation in 38 Patients
Paulus, Patrick; Sambon, A.; Vivegnis, Danielle et al

in Laryngoscope (1998), 108(10), 1578-83

OBJECTIVES: To evaluate the clinical usefulness of FDG-PET (fluoro-2-deoxy-glucose-positron emission tomography) in the detection of lymph node involvement and recurrences in patients with head and neck ... [more ▼]

OBJECTIVES: To evaluate the clinical usefulness of FDG-PET (fluoro-2-deoxy-glucose-positron emission tomography) in the detection of lymph node involvement and recurrences in patients with head and neck cancer. STUDY DESIGN: Retrospective review of 38 patients with biopsy-proven head and neck cancers who underwent clinical, computed tomography (CT), and FDG-PET examinations. Twenty-five patients were studied prior to therapy and 13 patients were evaluated for disease recurrence. METHODS: All patients were operated and clinical data, CT, and FDG-PET results were correlated with histopathological findings. RESULTS: All primary tumors in 25 patients were detected, with the exception of one small superficial localization of the epiglottis. Histopathological examination showed lymph node involvement in 10 patients; PET detected lymph node involvement in five. FDG-PET found one case of nodal disease not identified by clinical and CT examination. With so few cases, this could be anecdotal. Five false-negative results (microscopic lymph node involvement) and two false positives were noted. Twelve of 13 patients with recurrent disease were correctly identified with FDG-PET. FDG-PET was the only imaging technique to identify local recurrence in two patients and lymph node involvement in two others. One false-positive result occurred in a patient with a foreign body granuloma. CONCLUSIONS: FDG-PET is a useful diagnostic modality for the detection of recurrent tumors and, in selected cases, precise lymph node involvement. The best way to further investigate the utility of clinical FDG-PET is in the follow-up of treated patients. [less ▲]

Detailed reference viewed: 39 (1 ULg)
Full Text
Peer Reviewed
See detailClinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases.
Hustinx, Roland ULg; Paulus, Patrick; Jacquet, Nicolas et al

in Annals of Oncology (1998), 9(4), 397-401

BACKGROUND: Assessment of metastatic involvement of the liver remains a diagnostic challenge. The objective of this study was to evaluate the potential role of FDG PET in the detection of liver metastases ... [more ▼]

BACKGROUND: Assessment of metastatic involvement of the liver remains a diagnostic challenge. The objective of this study was to evaluate the potential role of FDG PET in the detection of liver metastases. PATIENTS AND METHODS: Sixty-four patients with malignancy and possible liver involvement were included. Liver metastases were present in 31 cases, demonstrated by histopathological analysis in 15 cases and by follow-up in 16 cases. The negative cases were confirmed by pathology in four cases, peroperative ultrasonography in 12 cases, and follow-up in 17 cases. Whole-body FDG PET was compared to CT (n = 53) and US (n = 43). RESULTS: PET demonstrated a 97% sensitivity, an 88% specificity and a 92% accuracy, compared to 93%, 75% and 85%, respectively, for CT (P = NS). Concordant results were obtained in 44 of 64 patients (69%: 19 TP. 25 TN). PET provided new and accurate information in 15 of 64 patients (23.4%). PET demonstrated liver metastases in 11 patients in whom conventional methods yielded negative (two cases) or doubtful (nine cases) results. Four patients free of liver involvement were correctly staged with PET, while CT/US were equivocal. PET was erroneous in five of 64 cases (7.8%, four FP, one FN). CONCLUSIONS: FDG PET allows an accurate screening of liver involvement in patients with malignancy. Combined with CT, it provides additional diagnostic information that could directly affect the management of these patients. [less ▲]

Detailed reference viewed: 32 (13 ULg)
Full Text
Peer Reviewed
See detailWhole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer.
Bury, Thierry ULg; Dowlati, A.; Paulus, Patrick et al

in European Respiratory Journal (1997), 10(11), 2529-34

Despite advances in morphological imaging, some patients with lung cancer are found to have nonresectable disease at surgery or die of recurrence within yr of surgery. We performed a prospective study in ... [more ▼]

Despite advances in morphological imaging, some patients with lung cancer are found to have nonresectable disease at surgery or die of recurrence within yr of surgery. We performed a prospective study in 109 patients to compare the accuracy of whole-body positron emission tomography (PET) using fluorine-18 deoxyglucose (18FDG) and conventional imaging (CI) methods for the staging of non-small cell lung cancer (NSCLC). When CI or PET study suggested metastatic disease, confirmation was obtained by biopsy or follow-up information. As compared to CI, 18FDG-PET correctly changed the N stage in 22 patients (33%) and the M stage in 15 patients (14%). For the detection of distant metastases, PET study showed five false-positive sites and no false-negative cases. Currently, the accuracy of PET in the detection of M stage is 96%. Our study shows that visual interpretation of whole-body fluorine-18 deoxyglucose-positron emission tomography images can improve the diagnostic accuracy in the staging of non-small cell lung cancer. Further experience is needed to establish if metabolic imaging would be a cost-effective tool in the future management of lung cancer. [less ▲]

Detailed reference viewed: 26 (2 ULg)
Full Text
See detailClinical PET in Oncology
Rigo, Pierre ULg; Paulus, Patrick; Bury, Thierry ULg et al

in Bergmann, H.; Kroiss, A.; Sinzinger H (Eds.) Radioactive Isotopes in Clinical Medicine and Research (1997)

18-FDG is accumulated in cancer cells. It has been proven useful to image a variety of tumors in conjunction with whole-body positron emission tomography. This review details somes of the indications of ... [more ▼]

18-FDG is accumulated in cancer cells. It has been proven useful to image a variety of tumors in conjunction with whole-body positron emission tomography. This review details somes of the indications of PET at various stages of the cancerous process : differential diagnosis, preoperative staging, diagnosis of residual or recurrent disease as well as follow-up of therapy. Consideration of several potential improvements in clinical PET and of the need for careful patients selection conclude this review. [less ▲]

Detailed reference viewed: 50 (7 ULg)
Full Text
Peer Reviewed
See detailOncological Applications of Positron Emission Tomography with Fluorine-18 Fluorodeoxyglucose
Rigo, Pierre ULg; Paulus, Patrick; Kaschten, Bruno et al

in European Journal of Nuclear Medicine (1996), 23(12), 1641-74

Positron emission tomography (PET) is now primarily used in oncological indication owing to the successful application of fluorine-18 fluorodeoxyglucose (FDG) in an increasing number of clinical ... [more ▼]

Positron emission tomography (PET) is now primarily used in oncological indication owing to the successful application of fluorine-18 fluorodeoxyglucose (FDG) in an increasing number of clinical indications at different stages of diagnosis, and for staging and follow-up. This review first considers the biological characteristics of FDG and then discusses methodological considerations regarding its use. Clinical indications are considered, and the results achieved in respect of various organs and tumour types are reviewed in depth. The review concludes with a brief consideration of the ways in which clinical PET might be improved. [less ▲]

Detailed reference viewed: 40 (1 ULg)
Full Text
Peer Reviewed
See detailComment j'explore ... une suspicion de cancer broncho-pulmonaire par tomographie a émission de positrons
Bury, Thierry ULg; Paulus, Patrick; Weber, Thierry et al

in Revue Médicale de Liège (1996), 51(4), 317-9

Detailed reference viewed: 41 (10 ULg)
Full Text
Peer Reviewed
See detailStaging of Non-Small-Cell Lung Cancer by Whole-Body Fluorine-18 Deoxyglucose Positron Emission Tomography
Bury, Thierry ULg; Dowlati, A.; Paulus, Patrick et al

in European Journal of Nuclear Medicine (1996), 23(2), 204-6

Positron emission tomography (PET) using fluorine-18 deoxyglucose (FDG), showing increased FDG uptake and retention in malignant cells, has been proven useful to differentiate malignant from benign tissue ... [more ▼]

Positron emission tomography (PET) using fluorine-18 deoxyglucose (FDG), showing increased FDG uptake and retention in malignant cells, has been proven useful to differentiate malignant from benign tissue. We undertook a prospective study in 61 patients to compare the accuracy of whole-body FDG PET and conventional imaging (CI) methods for the staging of non-small-cell lung cancer (NSCLC). CI included chest and abdomen computed tomographic scanning and bone scintigraphy. When CI or PET study suggested metastatic disease, confirmation was obtained by biopsy or clinical or radiological follow-up. As compared to CI, PET correctly changed the N stage in 13 patients (21%) and the M stage in six patients (10%). There were three false-positive and no false-negative distant PET findings. Our preliminary results show that whole-body FDG PET can improve the diagnostic accuracy in the staging of NSCLC. [less ▲]

Detailed reference viewed: 11 (1 ULg)
Full Text
Peer Reviewed
See detailComparison of positron emission tomography and computed tomography in the mediastinal and extrathoracic staging of non-small cell lung cancer
PAULUS, Patrick; BURY, Thierry ULg; HUSTINX, Roland ULg et al

in Journal of Nuclear Medicine (The) (1996), 37

Comparison of positron emission tomography and computed tomography in the mediastinal and extrathoracic staging of non-small cell lung cancer

Detailed reference viewed: 9 (0 ULg)